Regavirumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | cytomegalovirus glycoprotein B |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
Regavirumab is a human monoclonal antibody against infections with cytomegalovirus.[1]
References
[edit]- ^ Arizono H, Sugano T, Kaida S, Shibusawa K, Karasawa Y, Esumi Y, et al. (July 1994). "Pharmacokinetics of a new human monoclonal antibody against cytomegalovirus. Third communication: correspondence of the idiotype activity and virus neutralization activity of the new monoclonal antibody, regavirumab in rat serum and its pharmacokinetics in rats and monkeys". Arzneimittel-Forschung. 44 (7): 909–13. PMID 7945531.
 | This antiinfective drug article is a stub. You can help Wikipedia by expanding it. |
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |